JP2023536086A5 - - Google Patents
Info
- Publication number
- JP2023536086A5 JP2023536086A5 JP2023505707A JP2023505707A JP2023536086A5 JP 2023536086 A5 JP2023536086 A5 JP 2023536086A5 JP 2023505707 A JP2023505707 A JP 2023505707A JP 2023505707 A JP2023505707 A JP 2023505707A JP 2023536086 A5 JP2023536086 A5 JP 2023536086A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- bispecific molecule
- ctla
- use according
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063057054P | 2020-07-27 | 2020-07-27 | |
| US63/057,054 | 2020-07-27 | ||
| US202163177036P | 2021-04-20 | 2021-04-20 | |
| US63/177,036 | 2021-04-20 | ||
| US202163219066P | 2021-07-07 | 2021-07-07 | |
| US63/219,066 | 2021-07-07 | ||
| PCT/US2021/042901 WO2022026306A1 (en) | 2020-07-27 | 2021-07-23 | Methods for the use of a pd-1 x ctla-4 bispecific molecule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023536086A JP2023536086A (ja) | 2023-08-23 |
| JP2023536086A5 true JP2023536086A5 (cg-RX-API-DMAC7.html) | 2024-07-29 |
Family
ID=80036053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023505707A Pending JP2023536086A (ja) | 2020-07-27 | 2021-07-23 | Pd‐1×ctla‐4二重特異性分子の使用のための方法 |
Country Status (13)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120648657A (zh) * | 2024-03-08 | 2025-09-16 | 上海锦斯生物技术有限公司 | 一种修饰的溶瘤病毒及其组合物 |
| WO2026021409A1 (zh) * | 2024-07-22 | 2026-01-29 | 宜明昂科生物医药技术(上海)股份有限公司 | 靶向ctla-4、pd-l1和vegf的肿瘤联合疗法 |
| WO2026067794A1 (en) * | 2024-09-30 | 2026-04-02 | Shen Shi Pharmaceuticals (Shanghai) Co., Ltd. | Trispecific antibodies and uses thereof |
| WO2026117666A1 (en) * | 2024-11-26 | 2026-06-04 | Dana-Farber Cancer Institute, Inc. | Bispecific antibodies for treating cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| PE20231958A1 (es) * | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| CN108367069B (zh) * | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| US20190241658A1 (en) * | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
| IL321475A (en) * | 2016-05-06 | 2025-08-01 | Medimmune Llc | Bispecific binding proteins and their uses |
| CA3026151A1 (en) * | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| WO2019179421A1 (en) * | 2018-03-19 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/ctla-4 antibody molecules |
| US20210079094A1 (en) * | 2019-03-29 | 2021-03-18 | Xencor, Inc. | Dosing of a bispecific antibody that binds pd1 and ctla4 |
-
2021
- 2021-07-23 KR KR1020237004873A patent/KR20230042038A/ko active Pending
- 2021-07-23 CA CA3189926A patent/CA3189926A1/en active Pending
- 2021-07-23 MX MX2023001111A patent/MX2023001111A/es unknown
- 2021-07-23 IL IL300166A patent/IL300166A/en unknown
- 2021-07-23 CN CN202180059321.7A patent/CN116134053A/zh active Pending
- 2021-07-23 EP EP21849290.8A patent/EP4188961A4/en active Pending
- 2021-07-23 WO PCT/US2021/042901 patent/WO2022026306A1/en not_active Ceased
- 2021-07-23 TW TW110127252A patent/TW202220691A/zh unknown
- 2021-07-23 US US18/006,294 patent/US20230312756A1/en active Pending
- 2021-07-23 BR BR112023001487A patent/BR112023001487A2/pt unknown
- 2021-07-23 AU AU2021316192A patent/AU2021316192A1/en active Pending
- 2021-07-23 JP JP2023505707A patent/JP2023536086A/ja active Pending
-
2023
- 2023-01-18 ZA ZA2023/00822A patent/ZA202300822B/en unknown